

## SUPPLEMENTARY MATERIAL

### FIGURES

*Fig S1. Frequency of cases with confirmatory molecular diagnosis for Ataxia. A. Autosomal Dominant Ataxias. B. Autosomal Recessive Ataxias*

### TABLES

*Table S1. Patients with Autosomal Dominant Ataxias*

Patient	Sex	Age	AO	Evolution (years)	Family History	Molecular diagnosis	Gene	Mutation	Methodology
1	F	39	38	1	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion. (32/54 repeats)	PCR and capillary electrophoresis
2	F	30	28	2	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (31/48 repeats)	PCR and capillary electrophoresis
3	F	29	29	0	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (32/53 repeats)	PCR and capillary electrophoresis

4	F	45	38	7	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (30/50 repeats)	PCR and capillary electrophoresis
5	M	39	30	9	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (30/48 repeats)	PCR and capillary electrophoresis
6	F	55	49	6	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion(29/ 43 repeats)	PCR and capillary electrophoresis
7	M	40	36	16	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (30/52 repeats)	PCR and capillary electrophoresis
8	F	61	45	16	Yes	SCA1	<i>ATXN1</i>	Abnormal CAG trinucleotide repeat expansion (29/42 repeats)	PCR and capillary electrophoresis
9	M	59	45	14	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (20/38 repeats)	PCR and capillary electrophoresis
10	M	30	23	7	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/43 repeats)	PCR and capillary electrophoresis
11	M	35	22	13	No	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion(22/43 repeats)	PCR and capillary electrophoresis
12	M	35	23	12	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/43 repeats)	PCR and capillary electrophoresis

13	F	14	13	1	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/51 repeats)	PCR and capillary electrophoresis
14	F	47	40	7	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/39 repeats)	PCR and capillary electrophoresis
15	F	56	40	16	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/44 repeats)	PCR and capillary electrophoresis
16	F	25	23	2	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/40 repeats)	PCR and capillary electrophoresis
17	F	31	25	6	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/44 repeats)	PCR and capillary electrophoresis
18	F	26	11	15	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/51 repeats)	PCR and capillary electrophoresis
19	M	30	19	11	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion(22/40 repeats)	PCR and capillary electrophoresis
20	M	23	10	13	Yes	SCA2	<i>ATXN2</i>	Expansión anormal de la repetición de trinucleótidos CAG (22/52 repeats)	PCR and capillary electrophoresis
21	M	69	60	9	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/37 repeats)	PCR and capillary electrophoresis

22	M	51	47	4	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/38 repeats)	PCR and capillary electrophoresis
23	M	57	50	7	No	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/40 repeats)	PCR and capillary electrophoresis
24	M	21	18	3	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/44 repeats)	PCR and capillary electrophoresis
25	M	46	18	26	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/39 repeats)	PCR and capillary electrophoresis
26	F	48	15	3	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/39 repeats)	PCR and capillary electrophoresis
27	F	25	20	5	Yes	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/44 repeats)	PCR and capillary electrophoresis
28	M	44	30	14	YES	SCA2	<i>ATXN2</i>	Abnormal CAG trinucleotide repeat expansion (22/44repeats)	PCR and capillary electrophoresis
29	M	45	35	10	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (23/64 repeats)	PCR and capillary electrophoresis
30	M	55	51	4	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (19/63 repeats)	PCR and capillary electrophoresis

31	F	34	32	2	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (23/71 repeats)	PCR and capillary electrophoresis
32	F	32	30	2	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (23/71 repeats)	PCR and capillary electrophoresis
33	F	48	36	12	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (31/62 repeats)	PCR and capillary electrophoresis
34	M	51	44	7	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (10/62 repeats)	PCR and capillary electrophoresis
35	M	65	39	26	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (19/62 repeats)	PCR and capillary electrophoresis
36	M	56	50	6	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (10/63 repeats)	PCR and capillary electrophoresis
37	M	33	31	2	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (10/67 repeats)	PCR and capillary electrophoresis
38	F	53	49	4	Yes	SCA3	<i>ATXN3</i>	Abnormal CAG trinucleotide repeat expansion (20/66 repeats)	PCR and capillary electrophoresis
39	F	66	63	3	Yes	SCA6	<i>CACNA1A</i>	Abnormal CAG trinucleotide repeat expansion (9/20 repeats)	PCR and capillary electrophoresis

40	F	38	34	4	Yes	SCA6	<i>CACNA1A</i>	Abnormal CAG trinucleotide repeat expansion (10/21 repeats)	PCR and capillary electrophoresis
41	F	74	55	15	Yes	SCA6	<i>CACNA1A</i>	Abnormal CAG trinucleotide repeat expansion (4/21 repeats)	PCR and capillary electrophoresis
42	F	37	27	10	Yes	SCA7	<i>ATXN7</i>	Abnormal CAG trinucleotide repeat expansion (7/66 repeats)	PCR and capillary electrophoresis
43	M	49	37	19	Yes	Huntington disease	<i>HTT</i>	Abnormal CAG trinucleotide repeat expansion (20/39 repeats)	PCR and capillary electrophoresis
44	F	23	20	3	Yes	Huntington disease	<i>HTT</i>	Abnormal CAG trinucleotide repeat expansion (10/62 repeats)	PCR and capillary electrophoresis
45	F	40	32	8	Yes	Gerstmann-Sträussler Scheinker disease	<i>PRNP</i>	NM_000311.3:c.305C>T(p.Pro102Leu)	PCR and sanger sequencing
46	F	52	47	6	Yes	Gerstmann-Sträussler Scheinker disease	<i>PRNP</i>	NM_000311.3:c.305C>T(p.Pro102Leu)	PCR and Sanger sequencing
47	F	28	24	4	Yes	Gerstmann-Sträussler Scheinker disease	<i>PRNP</i>	NM_000311.3:c.305C>T(p.Pro102Leu)	PCR and Sanger sequencing

48	M	41	37	4	Yes	Gerstmann-Sträussler Scheinker disease	<i>PRNP</i>	NM_000311.3:c.350C>T(p.Ala117Val)	PCR Sanger Sequencing
49	F	51	41	10	Yes	SCA28	<i>AFG3L2</i>	NM_006796:c.2114T>C(p.Ille705Thr)	NGS
50	M	5	1m	5	Yes	Ataxia related to <i>SCNA2</i> gene	<i>SCN2A</i>	NM_021007.2: c.788C>T (p.Ala263Val)	NGS
51	F	2	<1	2	Yes	Ataxia related to <i>SCNA2</i> gene	<i>SCN2A</i>	NM_021007.2:c.788C>T (p.Ala263Val)	PCR Sanger Sequencing
52	M	38	<1	38	Yes	Ataxia related to <i>SCNA2</i> gene	<i>SCN2A</i>	NM_021007.2:c.788C>T (p.Ala263Val)	PCR Sanger Sequencing
53	F	66	19	45	Yes	SCA36	<i>NOP56</i>	Abnormal hexanucleotide GGCCTG repeat expansion	TP-PCR and capillary electrophoresis
54	F	2	8m	1	No	Ataxia and epilepsy associated to <i>KCN2A</i> gene	<i>KCN2A</i>	NM_001204269 c.890G>A (p.Arg297Gln)	NGS
55	M	45	44	4	Yes	SCA48	<i>STUB1</i>	NM_005861.3:c.854C>A (p.Ala285Asp)	NGS

---

**NGS:**Next Generation Sequencing **P:** patients **M:** Male **F:**female; **m:**months; **AO:** age at onset in years



**TABLE S2. Eye movement abnormalities in patients with Autosomal Dominant Ataxias**

	SCA-1 (N:8)		SCA-2 (N:20)		SCA-3 (N:10)		SCA-6 (N:3)		SCA-7 (N:1)		SCA 36 (N:1)		SCA-28 (N:1)		GSS (N:4)		HD (N:2)	
	H	V	H	V	H	V	H	V	H	V	H	V	H	V	H	V	H	V
<b>Impaired Smooth Pursuit *</b>	3	2	7	5	2	1	-	-	1	1	-	-	1	1	2	2	1	-
<b>Saccades *</b>																		
• <b>Prolonged latency</b>	-	-	9	5	1	1	-	-	-	-	-	-	-	-	-	-	2	2
• <b>Slow saccades</b>	2	1	16	12	3	1	-	-	-	-	1	1	-	-	2	2	2	2
• <b>Dysmetria</b>																		
• <b>-Hipometric</b>	1	1	5	7	3	2	-	-	-	-	1	1	-	-	2	2	2	1
• <b>-Hipermetric</b>	1	-	2	2	2	1	-	-	-	-	-	-	1	1	-	-	-	-
<b>Nystagmus *</b>	-	-	4	2	6	1	1	-	1	1	-	-	-	-	-	1	1	-

SCA: Spinocerebellar Ataxia; **H**: Horizontal; **V**: Vertical; **N**: Number of patients of each subtype of SCA; **HD**: Huntington disease. **GSS**: Gerstmann-Sträussler Scheinker disease; \* Number of affected patients

**TABLE S3** Extra-cerebellar manifestations in patients with Autosomal Dominant Ataxias.

<i>Type of Ataxia</i>	<b>SCA-1</b> <b>(N:8)</b>	<b>SCA-2</b> <b>(N:20)</b>	<b>SCA-3</b> <b>(N:10)</b>	<b>SCA-6</b> <b>(N:3)</b>	<b>SCA-7</b> <b>(N:1)</b>	<b>HD</b> <b>(N:2)</b>	<b>GSS</b> <b>(N:4)</b>	<b>SCA36</b> <b>(N:1)</b>	<b>SCA-28</b> <b>(N:1)</b>
<b>Visual loss</b>	-	-	-	-	1	-	-	-	-
<b>Pyramidal Signs</b>	4	4	3	1	-	-	2	-	1
<b>Polyneuropathy</b>	-	3	6	-	-	-	1	-	-
<b>Dystonia</b>	-	-	2	-	-	-	-	-	-
<b>Parkinsonism</b>	1	6	5	1	-	1	-	-	-
<b>Myoclonus</b>	-	2	1	-	-	-	1	-	-
<b>Chorea</b>	-	-	-	-	-	-	-	-	-
<b>Cognitive impairment</b>	-	-	-	-	-	1	1	-	-

**SCA:** Spinocerebellar Ataxia; **HD:** Huntington Disease; **GSS:** Gerstmann Straussler Scheinker Disease . **N:** Number of patients affected

*Table S4. Patients with Confirmatory molecular diagnosis for Autosomal Recessive Ataxia*

N	Gender	Age	Age onset	Disease Progression (in years)	Family history	Molecular Diagnostic	Gene	Mutation
1	M	26	12	14	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
2	M	23	12	11	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
3	M	22	16	6	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
4	F	14	8	6	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
5	M	22	5	17	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
6	F	36	17	19	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
7	F	75	20	55	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
8	M	18	14	4	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
9	F	37	13	24	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
10	M	32	23	9	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
11	M	48	17	31	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
12	F	26	5	11	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion

13	M	20	12	8	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
14	M	49	16	33	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
15	M	45	17	28	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
16	M	30	5	25	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
17	F	47	16	31	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
18	M	48	18	30	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion NM_000144.4:c.354C>G;(p.Tyr118Ter)
19	F	21	11	10	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
20	M	64	11	53	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
21	M	16	14	2	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
22	F	20	14	6	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
23	M	19	9	10	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
24	F	14	13	1	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
25	M	45	17	28	NO	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
26	F	39	30	9	NO	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
27	M	16	2	13	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion

28	F	11	5	6	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
29	F	45	12	33	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
30	F	23	15	8	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
31	M	25	22	3	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
32	F	21	17	4	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
33	M	12	9	3	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
34	M	32	24	8	No	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
35	F	18	17	1	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
36	M	20	16	3	Yes	Friedreich Ataxia	<i>FXN</i>	Abnormal GAA trinucleotide repeat expansion
37	F	29	21	8	No	Niemann Pick-C disease	<i>NPCI</i>	NM_000271.4: c.2872C>T;(p.Arg958Ter)
38	F	36	33	3	Yes	Niemann Pick-C disease	<i>NPCI</i>	NM_000271.5:c.1552C>T,(p.Arg518Trp ) NM_000271.5:c.3019C>G,(p.Pro1007Ala)
39	M	41	10	31	Yes	Niemann Pick-C disease	<i>NPCI</i>	NM_000271.5:c.1552C>T,(p.Arg518Trp ) NM_000271.5:c.3019C>G,(p.Pro1007Ala)
40	M	41	30	10	Yes	Niemann Pick-C disease	<i>NPCI</i>	NM_000271.5:c.1552C>T,(p.Arg518Trp ) NM_000271.5:c.3019C>G,(p.Pro1007Ala)
41	M	11	1	11	Yes	Ataxia with oculomotor apraxia type 1	<i>APTX</i>	NM_175069.1:c.879G>A;( p.Ter293=)
42	F	12	4	4	Yes	Ataxia with oculomotor apraxia type 1	<i>APTX</i>	NM_175069.1:c.879G>A;( p.Ter293=)

43	M	19	11	8	NO	Ataxia with oculomotor apraxia type 2	<i>SEXT</i>	NM_001351527:c.7154T>G;(p.Val2385Gly) ; NM_001351527.1:c.15_17delTTG (p.Cys5del)
44	F	26	15	11	NO	Ataxia with oculomotor apraxia type 2	<i>SEXT</i>	NM_001351527:c.1856_1863del;p.Asn620Rfs*4 ; NM_001351527.1:c.15_17delTTG (p.Cys5del)/NM_001351527:c.15_17del:p.C5Wfs*2673
45	M	21	5	16	No	Cerebrotendinous xanthomatosis	<i>CYP27A1</i>	NM_000784.3:c.1213C>T(p.Arg 405Trp)
46	M	24	17	7	NO	Spinocerebellar ataxia autosomal recessive type 16 (SCAR16)	<i>STUB1</i>	NM_005861·2:c.612+1G>C NM_005861·2:c.823C>G (p.Leu275Val)
47	M	29	19	10	Yes	Action myoclonus–renal failure syndrome	<i>SCARB2</i>	NM_005506:c.704+1G>A
48	M	26	24	2	Yes	Action myoclonus–renal failure syndrome	<i>SCARB2</i>	NM_005506:c.704+1G>A
49	F	32	2	30	Yes	Recessive Ataxia secondary to biallelic OPA1 mutations (OPA1)	<i>OPA1</i>	NM_015560: c.267G>T(p.Trp89Cys)NM_015560: c.635_636delAA (p.Lys212ArgfsTer4)
50	F	31	2	29	Yes	Recessive Ataxia secondary to biallelic OPA1 mutations (OPA1)	<i>OPA1</i>	NM_015560: c.267G>T(p.Trp89Cys); NM_015560: c.635_636delAA(p.Lys212ArgfsTer4)
51	M	4	<1 Year	4	Yes	Joubert Syndrome	<i>CC2D2A</i>	NM_001080522: c.4667A>T (p.Asp1556Val); NM_001080522:c.3289delG(p.Val1097PhefsTer2)
52	M	7	7 m	7	No	Ataxia Telangiectasia	<i>ATM</i>	NM_000051.3:c.6374 A>G (p.His2125Arg); NM_000051.3:c.2922-1G>A.

53	M	6	18 m	4	No	Ataxia Telangiectasia	<i>ATM</i>	NM_000051.3:c.614T>G (Leu205Ter); NM_000051.3 c.8827_8828delAC (p.Thr2473GlyfsTer3)
54	F	22	5	17	No	Ataxia Telangiectasia	<i>ATM</i>	NM_000051.3:c.1373G>A(p.Cys458Tyr); NM_000051:c.8785_8786delAGGT (p.Arg2929MetfsTfs*2)
55	M	24	2	22	No	Autosomal recessive spastic ataxia of Charlevoix-Saguenay	<i>SACS</i>	NM_001278055:c.4492C>T (p.Arg1498Ter); NM_001278055: c.2388dupA (p.Leu797IlefsTer5)
56	M	40	19	21	Yes	Autosomal recessive cerebellar ataxia type 1 (ARCA1)	<i>SYNE 1</i>	NM_033071.3: c.20314delC(p.Leu6772TrpfsTer13); NM_O33071.3: c.1980G>A; p.(Trp660Ter)
57	M	37	22	15	Yes	Autosomal recessive cerebellar ataxia type 1 (ARCA1)	<i>SYNE 1</i>	NM_033071.3: c.20314del;p.Leu6772Trpfs*13; NM_O33071.3: c.1980G>A; p.(Trp660Ter)
58	M	17	7	10	No	CLN2/Spinocerebellar ataxia autosomal recessive type SCAR 7	<i>TPP1</i>	NM_000391: exon7:c.827A>T(p.Asp276Val); NM_000391.3:c.887-10A>G

NGS:Next Generation Sequencing **P**: patients **M**: Male **F**:female





<b>Nistagmus</b>	10	2	-	-	2	1	-	-	-	-	1	-	2	-	-	-	-
<b>Oculomotor Apraxia</b>	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-
<b>Macro Square-Waves</b>	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**FA:** Friedreich's Ataxia, **AOA:** Ataxia with Oculomotor Apraxia **SJ:** Joubert Syndrome, **SMA-IR:** Action myoclonus-Renal Failure Syndrome **SCAR16: Spinocerebellar** Ataxia Autosomal recessive type 16: NPC: Niemann Pick type C disease ; **OPA:** Recessive Ataxia Secondary to biallelic OPA1 mutations; **AT:** Ataxia Telangiectasia, **ARSACS:** Autosomal Recessive Spastic Ataxia of Charlevoix – Saguenay; **H:** Horizontal; **V:** Vertical; **N:** Number of patients of each subtype of recessive ataxia; \* Number of affected patients.

**TABLE S7. Use of Next generation sequencing (NGS) techniques in the study of ataxic patients**

<b>Total of patients who were analyzed by NGS Techniques</b>	<b>26</b>
Total number of confirmatory molecular diagnosis	17/26 (65%)
Patients who were diagnosed by multigenic panel testing	10/14
Patients who were diagnosed by WES	6/11
Patients who were diagnosed by WGS	1/1

**WES:** Whole exome sequencing; **WGS:** Whole genome sequencing

